

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2836-D

Kenneth A. Brasel, Stewart D. Lyman,
Eugene Maraskovsky, Hilary J. McKenna,
David H. Lynch and Charles R.
Maliszewski

Group Art Unit: 1644

Examiner: F.P. VanderVegt

Serial No: 09/448,378

Filed: November 23, 1999

CPA Filed: June 28, 2001

For: DENDRITIC CELL STIMULATORY FACTOR

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The title of the invention at page 1 has been amended as follows:

DENDRITIC CELL STIMULATORY FACTOR Methods of Using Flt3-Ligand for Augmenting an Immune Response for the Treatment of Cancer

The cross-reference to related applications at page 1 has been amended as follows:

This is a divisional application of U.S. S/N 08/725,540 filed February 22, 1999, now abandoned, which is a continuation-in-part of U.S. S/N 08/539,142 filed October 4, 1995, now abandoned.

Please replace the paragraph at page 4, line 34 to page 5, line 3 with the following rewritten paragraph:

As used herein, the term "flt3-ligand" refers to a genus of polypeptides that are described in United States Patent No. 5,554,512, EP 0627487 A2 and in WO 94/28391, both incorporated herein by reference. A human flt3-ligand cDNA was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, Rockville, Maryland, USA

(ATCC) on August 6, 1993 and assigned accession number ATCC 69382. The deposit was made under the terms of the Budapest Treaty. Flt3-L can be made according to the methods described in the documents cited above.

In the Claims:

6. (Three times amended) A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient.

20. (Three times amended) A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient in an amount sufficient to enhance the patient's immune response to such disease and administering a tumor antigen to the patient.